TABLE 3.
Risk of Cancer in Children Conceived by ART Compared With Children Conceived Without ART, Norway, 1984–2011
| Cancer Site | ICCC Site Group | Total Number of Tumors | Crude | Model IIa | ||||
|---|---|---|---|---|---|---|---|---|
| ART | Non-ART | Total | HR | 95% CI | HR | 95% CI | ||
| Leukemiab | I | 17 | 1012 | 1029 | 1.52 | 0.94–2.45 | 1.67* | 1.02–2.73 |
| ALL | 1a | 9 | 768 | 777 | 1.03 | 0.53–1.98 | 1.16 | 0.60–2.27 |
| AML | 1b | 5 | 173 | 178 | 2.65* | 1.09–6.46 | 2.63* | 1.04–6.64 |
| Other leukemias | 1c–e | 3 | 71 | 74 | 4.91* | 1.53–15.7 | 5.13* | 1.50–7.60 |
| Lymphomac | II | 4 | 456 | 460 | 1.52 | 0.57–4.08 | 1.79 | 0.66–4.90 |
| Hodgkin's | IIa | 3 | 258 | 261 | 2.62 | 0.84–8.21 | 3.63* | 1.12–11.72 |
| Non-Hodgkin's | IIb | 1 | 147 | 148 | 0.93 | 0.13–6.69 | 0.99 | 0.14–7.28 |
| CNSc | III | 12 | 1007 | 1019 | 1.25 | 0.71–2.21 | 0.92 | 0.47–1.79 |
| Astrocytomas | IIIb | 5 | 362 | 368 | 1.71 | 0.76–3.83 | 1.45 | 0.63–3.29 |
| Embryonal CNS tumors | IIIc | 3 | 175 | 179 | 2.13 | 0.79–5.74 | 1.70 | 0.62–4.69 |
| Other gliomas | IIId | 1 | 104 | 105 | 1.17 | 0.16–8.40 | 1.19 | 0.16–8.80 |
| Other CNS tumors | IIIf | 1 | 132 | 133 | 0.43 | 0.60–3.06 | 0.50 | 0.07–3.59 |
| Neuroblastoma | IV | 4 | 184 | 188 | 1.52 | 0.56–4.08 | 1.79 | 0.64–4.99 |
| Retinoblastoma | V | 1 | 90 | 91 | 0.75 | 0.10–5.38 | — | — |
| Renal | VI | 3 | 251 | 254 | 1.37 | 0.44–4.28 | 1.40 | 0.44–4.48 |
| Hepatic | VII | 2 | 108 | 110 | 2.22 | 0.54–9.07 | 1.76 | 0.41–7.46 |
| Soft tissue | IX | 5 | 307 | 312 | 1.69 | 0.70–4.09 | 1.33 | 0.54–3.30 |
| Others | XI–XII | 3 | 488 | 491 | 1.10 | 0.35–3.44 | 1.21 | 0.38–3.82 |
| All | 49 | 4414 | 4463 | 1.27 | 0.90–1.63 | 1.21 | 0.90–1.63 | |
Cancers are classified by the third version of the ICCC. The proportional hazards assumption was tested with the Schoenfeld residuals.
Adjusted for birth year, birth order, maternal age at delivery, place of birth, gender, birth weight, and gestational age.
In summing up the total number of cancers, each case of lymphoma and leukemia is counted only once.
Analyses for sites with no cancer cases in the ART group were not performed and are therefore omitted from Table 3.
Significant HRs.